Invesco Ltd. lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 53.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,590,260 shares of the medical research company's stock after buying an additional 902,226 shares during the period. Invesco Ltd. owned 1.43% of IQVIA worth $509,012,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Synergy Asset Management LLC acquired a new stake in shares of IQVIA in the 4th quarter worth about $33,000. Lee Danner & Bass Inc. acquired a new stake in shares of IQVIA in the fourth quarter valued at approximately $44,000. Zions Bancorporation N.A. raised its holdings in shares of IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after buying an additional 85 shares during the last quarter. Versant Capital Management Inc boosted its position in shares of IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after buying an additional 93 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new position in shares of IQVIA during the fourth quarter worth approximately $60,000. Institutional investors and hedge funds own 89.62% of the company's stock.
Wall Street Analysts Forecast Growth
IQV has been the topic of a number of recent analyst reports. StockNews.com cut shares of IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Mizuho dropped their price target on shares of IQVIA from $242.00 to $210.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Truist Financial decreased their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a report on Thursday. Morgan Stanley boosted their target price on IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Finally, JPMorgan Chase & Co. decreased their price target on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research note on Tuesday, February 18th. Six research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $241.50.
View Our Latest Report on IQV
IQVIA Stock Up 3.5 %
Shares of IQVIA stock traded up $5.12 on Monday, reaching $150.67. 532,227 shares of the company were exchanged, compared to its average volume of 1,381,304. IQVIA Holdings Inc. has a one year low of $135.97 and a one year high of $252.88. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a 50-day moving average of $182.32 and a 200 day moving average of $199.38. The company has a market capitalization of $26.57 billion, a price-to-earnings ratio of 20.09, a PEG ratio of 1.99 and a beta of 1.46.
IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Stories
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
